High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

被引:131
作者
Bezieau, S
Devilder, MC
Avet-Loiseau, H
Mellerin, MP
Puthier, D
Pennarun, E
Rapp, MJ
Harousseau, JL
Moisan, JP
Bataille, R
机构
[1] Inst Biol, Genet Mol Lab, F-44093 Nantes 01, France
[2] Inst Biol, Hematol Lab, F-44093 Nantes 01, France
[3] Hop Hotel Dieu, Dept Clin Hematol, Nantes, France
关键词
NRAS; KRAS2; ARMS; multiple myeloma; plasma-cell leukemia; MGUS; incidence; mutation detection;
D O I
10.1002/humu.1177
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Using allele,specific amplification method (ARMS), a highly sensitive one-stage allele specific PCR, we have evaluated the incidence of NRAS and KRAS2 activating mutations (codons 12, 13, and 61) in 62 patients with either monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma. (MM), primary plasma-cell leukemia (P-PCL), and also in human myeloma cell lines (HMCL). NRAS and/or KRAS2 mutations were found in 54.5% of MM at diagnosis (but in 81% at the time of relapse), in 50% of P-PCL, and in 50% of 16 HMCL. In contrast, the occurrence of such mutations was very low in MGUS and indolent MM (12.50%). Of note, KRAS2 mutations were always more frequent than NRAS. The validity of the technique was assessed by direct sequencing of cell lines and of some patients. Multiple mutations found in two patients were confirmed by subcloning exon PCR amplification products, testing clones with our method, and sequencing them. Thus, these early mutations could play a major role in the oncogenesis of MM and P-PCL. Hum Mutat 18:212-224, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:212 / 224
页数:13
相关论文
共 54 条
[1]  
AHUJA HG, 1990, BLOOD, V75, P1684
[2]  
Andre MT, 1998, DIGEST DIS SCI, V43, P1339
[3]   RAS MUTATIONS IN HUMAN-MELANOMA - A MARKER OF MALIGNANT PROGRESSION [J].
BALL, NJ ;
YOHN, JJ ;
MORELLI, JG ;
NORRIS, DA ;
GOLITZ, LE ;
HOEFFLER, JP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (03) :285-290
[4]  
BARELI M, 1989, BLOOD, V73, P281
[5]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[6]  
BATAILLE RTC, 1993, SANGRE, V3, P92
[7]  
Billadeau D, 1997, CANCER RES, V57, P2268
[8]  
BILLADEAU D, 1995, CANCER RES, V55, P3640
[9]   Simplified hot start PCR [J].
Birch, DE ;
Kolmodin, L ;
Laird, WJ ;
McKinney, N ;
Wong, J ;
Young, KKY ;
Zangenberg, GA ;
Zoccoli, MA .
NATURE, 1996, 381 (6581) :445-446
[10]   Mutation analyses of KRAS exon 1 comparing three different techniques:: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction [J].
Bjorheim, J ;
Lystad, S ;
Lindblom, A ;
Kressner, U ;
Westring, S ;
Wahlberg, S ;
Lindmark, G ;
Gaudernack, G ;
Ekstrom, P ;
Roe, J ;
Thilly, WG ;
Borresen-Dale, AL .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1998, 403 (1-2) :103-112